Physician profile
Melisa A Wilson
NPI 1780618355
$214,027.53
in general payments reported to CMS, 2019-2025
13 companies · $50K in 2025
The $50K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26K · 2022: $35K · 2023: $49K · 2024: $54K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Consulting Fee: $41K · Travel and Lodging: $33K · Food and Beverage: $7,928 · Education: $59.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $71,800.50 |
| Consulting Fee | $40,836.33 |
| Travel and Lodging | $32,736.92 |
| Food and Beverage | $7,928.09 |
| Education | $59.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $88,206.98 | 2021-2025 | Remodulin, Tyvaso, Orenitram |
| Actelion Pharmaceuticals US, INC. | $79,011.48 | 2021-2025 | Uptravi, Opsumit, Opsynvi |
| Merck Sharp & Dohme LLC | $20,107.08 | 2022-2025 | Winrevair |
| Actelion Pharmaceuticals, Ltd | $13,215.50 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $9,736.46 | 2021-2024 | |
| Johnson & Johnson Health Care Systems INC. | $3,096.97 | 2023-2025 | Uptravi, Veletri, Opsumit |
| Medtronic, INC. | $272.24 | 2021-2023 | Harmony |
| Nuwellis, INC. | $128.32 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $95.29 | 2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $78.33 | 2025 | |
| Baxter Healthcare | $30.98 | 2023 | Hillrom - Life 2000 Ventilation System |
| Genentech USA, INC. | $24.26 | 2021 | |
| Pharmacosmos Therapeutics INC. | $23.64 | 2023 | Monoferric |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melisa Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.